Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial…
Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that was ongoing at data cutoff in 62.5 percent of the patients who entered the study with…